Strengthening a Drug Development Program Before the Next Milestone

In drug development, the next milestone often reveals how strong the current plan really is.

A program may appear to be moving forward. Vendors are active, studies are underway, analytical work is progressing, and timelines are being tracked. But as the program gets closer to IND-enabling studies, clinical supply, tech transfer, or later-stage manufacturing, gaps can become more visible.

A process that worked at small scale may not be ready for larger batches. An analytical method may need additional development before it can support release testing or validation. A supplier that was suitable early on may not be able to meet GMP expectations. Documentation may need to be strengthened for regulatory review. A vendor timeline may depend on assumptions that have not been fully tested.

These issues are common, but they can create significant delays if they are not identified and addressed early.

Why gaps appear as programs advance

Early development is often focused on speed, data generation, and practical decision-making. Teams need to move efficiently, control cost, and get enough information to support the next step.

That approach can work well in the early stages. However, as a program advances, expectations become more complex. The work must become more connected across process chemistry, analytical development, formulation, quality, manufacturing, supply chain, and regulatory planning.

Each decision affects the next one.

A process change can impact impurity control. An analytical delay can affect release testing. A raw material issue can affect manufacturing timelines. A formulation decision can affect stability. A documentation gap can create questions during regulatory preparation.

When these areas are managed separately, the sponsor may not see the full picture until the program is already under timeline pressure.

Vendor activity is not the same as program readiness

One of the biggest challenges for sponsors is that activity can look like progress.

A CRO may be completing studies. A CDMO may be producing materials. An analytical lab may be generating data. But if these activities are not aligned with the broader CMC strategy, the program may still have unresolved risks.

Sponsors need to know whether the work being completed today will support the next milestone. That requires more than status updates. It requires technical oversight, clear ownership, realistic timelines, and an understanding of how each workstream connects to the larger development plan.

Without that structure, sponsors may encounter problems late in the process, when options are more limited and solutions are more expensive.

Where additional CMC support can add value

For many small and mid-sized biotech and pharmaceutical companies, internal teams are lean. One person may be responsible for managing several vendors, reviewing technical updates, preparing for investor discussions, tracking budgets, and keeping the program moving toward regulatory or clinical goals.

Experienced CMC support can help reduce that burden and bring more structure

to the program.

The purpose is not simply to point out problems. The goal is to help sponsors understand what needs to happen next and connect them with the technical expertise and supplier resources needed to move forward.

Moving from reactive to proactive

The most expensive development issues are often the ones found too late.

If a method is not ready, a supplier cannot support the next phase, a process does not scale, or documentation is incomplete, the sponsor may need to repeat work, add vendors, revise timelines, or adjust regulatory plans.

A proactive CMC approach helps identify these risks earlier, while there is still time to solve them in a practical way.

By strengthening the plan before the next milestone, sponsors can make better decisions, improve vendor coordination, reduce avoidable delays, and create a clearer path for development.

How DDA supports development programs

Drug Discovery Alliances helps biotech and pharmaceutical companies strengthen their development programs through experienced CMC consultants and a global network of preferred suppliers.

DDA supports sponsors across CMC strategy, vendor selection, technical oversight, analytical planning, process development, formulation, regulatory preparation, supplier coordination, and project management. Whether a company is preparing for IND-enabling work, clinical supply, tech transfer, or later-stage development, DDA can help identify gaps, recommend solutions, and connect the right resources to the program.

The best time to strengthen a development plan is before the next milestone depends on it.